Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BHVN
BHVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BHVN News
Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies
Jan 21 2026
Benzinga
RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside
Jan 21 2026
CNBC
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data
Jan 15 2026
Benzinga
Biohaven Highlights Portfolio Progress at 44th Annual J.P. Morgan Healthcare Conference
Jan 12 2026
PRnewswire
Biohaven Reports Positive Clinical Results for TRAP Degrader in IgA Nephropathy Patients
Jan 12 2026
Newsfilter
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 07 2026
PRnewswire
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 07 2026
Newsfilter
VHT ETF Sees Notable Insider Buying in Fortrea and Biohaven Holdings
Jan 06 2026
NASDAQ.COM
Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010
Jan 02 2026
Benzinga
Broadcom Options Volume Hits 217,460 Contracts, Significantly Above Average
Dec 26 2025
NASDAQ.COM
Biohaven's BHV-7000 Fails Phase 2 Depression Study Endpoint
Dec 26 2025
Benzinga
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Biohaven Reports Phase 2 Study Failure for BHV-7000, Stock Drops
Dec 26 2025
Benzinga
Biohaven's BHV-7000 Fails Phase 2 Depression Trial, Shares Drop 15.45%
Dec 26 2025
Benzinga
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
Dec 26 2025
Benzinga
Key Stock Market Movers: Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and Others
Dec 26 2025
Barron's
Show More News
